SynbiCITE Centre

At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: Imperial College - London
  • Initiator Type: Academia
  • No disease focus
  • Location: Europe
SynbiCITE

Abstract

Synthetic Biology Innovation Commercial and Industrial Translation Engine (SynbiCITE) is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. The IKC is an internationally recognized lead center in industrializing synthetic biology research, giving the U.K. a globally renowned national resource of interacting partners from across the U.K.’s leading academic institutions, industry, and business.

Mission

SynbiCITE is focused at Imperial College London and is accelerating the commercialization of world-class science and the emerging technologies encompassed by synthetic biology into new products, tools, processes, and services.

The overall aim is to grow U.K. industry in the sector and improve synthetic biology, using industry to achieve significant economic impact, generate wealth for the companies, generate skilled workers, and create jobs. This will, in turn, show the value of public investment in synthetic biology through economic growth and the societal and environmental advantages resulting from the technology development in the U.K.

SynbiCITE and partners across the U.K. and globally are committed to developing this technology through responsible innovation, which encompasses ethical, societal, and environmental considerations.

Impact/Accomplishment

SynbiCITE offers several training programs including LEAP (Synthetic Biology Leadership Excellence Accelerator Program), Lean Launchpad for Synthetic Biology, Three Day MBA: Developing entrepreneurship in synthetic biology, DNA synthesis and tools, and Project Management for Biotech.
See http://synbicite.com/training/

Points of Contact

SynbiCITE
Imperial College Incubator
Level 1 Bessemer Building
Imperial College London
London SW7 2AZ

CEO
Stephen Chambers
phone: +44 (0)20 7594 5910
phone: +44 (0)7518 404 104 (mobile)      

Commercial Director
John Collins
phone: +44 (0)20 7594 5800
phone: +44 (0)7876 750 624 (mobile)

Sponsors & Partners

Aberystwyth University

Agilent Technologies UK Ltd.

Algenuity

Algipharma AS

Bangor University

Biosyntha Technologies Ltd.

Cardiff University

Chain Biotech

Committed Capital Financial Services Ltd.

Defence Science and Technology Laboratory

DR Reddy’s Laboratories (EU) Ltd.

Fujifilm Diosynth Biotechnologies (UK) Ltd.

GlaxoSmithKline R&D Ltd.

Green Biologics Ltd.

Hockley International Ltd.

Imperial College London

Ingenza Ltd.

Kings College London

LabGenius

Lisk & Jones Consultants Ltd.

Lonza Biologics PLC

Microsoft Research Ltd.

Morph BioInformatics Ltd.

New Generation Biogas (NGB) Ltd.

Newcastle University

New-Food Innovation

Oil Plus Ltd.

Oxitec Ltd.

OxSyBio Ltd.

Procter & Gamble Technical Centres Ltd.

Prokarium Ltd.

Pulse Medical Technologies Ltd.

Queen’s University of Belfast

Royal College of Art

Shell Global Solutions UK

Sphere Fluidics Ltd.

Suterra UK

Swansea University

Syngenta Ltd.

Synpromics Ltd.

Synthace Ltd.

University College London

University of Birmingham

University of Bristol

University of Cambridge

University of Edinburgh

University of Exeter

University of Glasgow

University of Oxford

University of Sheffield

Visbion Ltd.

Warwick University


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.